Cara Therapeutics Q1 2024 net loss $0.56/shr, revenue $2.1M; NP data by end 2Q24

Tvardi Therapeutics, Inc.

2024-Q1 EPS reported -$0.56 revenue$2,135,000

Net loss $30.7M ($0.56/shr) vs $26.7M ($0.49) in Q1 2023; total revenue $2.1M down from $6.2M.
Cash & marketable securities $69.8M at March 31, 2024, down from $100.8M at Dec 31, 2023; ops used $30.5M.
KOURAGE 1 Part A topline NP results expected by end of Q2 2024; 214 patients enrolled, not powered for significance.
KORSUVA injection net sales $1.8M in Q1 2024; TDAPA expired March 31, now reimbursed via ESRD bundle.
Restructuring expenses $2.4M related to workforce reduction; R&D $22.0M vs $24.3M a year ago.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.999

Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income $30.7 million, EPS $(0.56) per basic and diluted share.

Period: first quarter ended March 31, 2024
Revenue: $2.1 million
Net income: $30.7 million
EPS: $(0.56) per basic and diluted share
Result: reported results

Exact text from the filing

or $(0.56) per basic and diluted share, compared to net loss of $26.7 million, or ($0.49) per basic and diluted share, for the same period in 2023. Revenues: Total revenue was $2.1 million and $6.2 million for the three months ended March 31, 2024 and 2023, respectively. Revenue primarily consisted of: · $0.8 million and $2.8 million of collaborative revenue

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.